Observational study · people

Follistatin-344: CSCR eye disorder in 11 bodybuilders after injection

Checked against the paper Observational studyPublished by PepVault

The takeaway

This paper links high-dose follistatin-344 injections to a fluid-under-the-retina eye condition in bodybuilders, which cleared after a single use but came back in those who injected more than once.

Kind
Observational study
Studied in
People
Number studied
11
Published
2020
Journal
Int Ophthalmol

What they tested

The team set out to describe bodybuilders who developed central serous chorioretinopathy (CSCR, fluid building up under the retina that blurs vision) after injecting high doses of follistatin-344 to gain muscle.

How the study was done

A retrospective case series, a look back at medical records, from one eye clinic. It covered 11 bodybuilding athletes who came in with worse vision after high-dose follistatin-344 injections and had eye scans (optical coherence tomography) that matched CSCR.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Follistatin-344? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

All 11 patients were men, with a mean age of 36.8 ± 8.1 years, and each had injected whole 1 mg vials of follistatin-344 under the skin of the belly. Most had injected a high dose only once, while a few had injected more than once. Most had CSCR in one eye at diagnosis, and one patient had it in both eyes. In every patient who had injected only once, the fluid under the retina fully cleared after an average of 2.3 ± 0.7 months and symptoms eased, while every patient who had injected more than once had CSCR come back.

What it doesn’t show

This is a small look-back series from one clinic with no comparison group, so it can't show that follistatin-344 caused CSCR or how often it happens. It only included men who already came in with vision problems.

The paper

Dağ et al. Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series. Int Ophthalmol. 2020.

The compound

More studies on Follistatin-344

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Follistatin-344? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo